Canopus BioPharma Incorporated
Canopus BioPharma Incorporated
Your view on CBIA
Overview
What the company does, where it operates, and who runs it.
About Canopus BioPharma Incorporated
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Patrick T. Prendergast
- Headquarters
- 233 Wilshire Boulevard, Santa Monica, CA, US
- Industry
- Medical - Pharmaceuticals
- Sector
- Healthcare
- CEO
- Patrick T. Prendergast
- Headquarters
- 233 Wilshire Boulevard, Santa Monica, CA, US
Canopus BioPharma Incorporated, a pharmaceutical research company, provides pharmaceutical products and assay methods to patients suffering from infectious, cancer, and addiction diseases. It also provides antivirals, radiation protection products, oncology products, bio-barcode assays, camelidae blood products, and neutraceutricals.
The company was founded in 1996 as Canopus Corporation and changed its name in 2007. Canopus BioPharma Incorporated is based in Santa Monica, California.
Media
Infographics, videos, and posts covering the company.
Stock Data
Price chart, volume, and trading data.
Fair Value
What FRC thinks it is worth vs. the current price.
FRC's fair value estimate for Canopus BioPharma Incorporated, and the rating behind it. CBIA last traded at $0.0001; the estimate is read against that market price. FRC analysts run the firm's valuation model across the companies on this platform to estimate what each one is worth, rather than republishing a consensus average. Shows the current estimate, our rating, and when it was last revised. A free account covers 7 company valuations a month; a paid subscription is unlimited.
Financial Ratios
Profitability, returns, valuation, and leverage ratios.
Valuation, profitability, liquidity and leverage ratios for Canopus BioPharma Incorporated. Starting points for Canopus BioPharma Incorporated: EPS -$0.0070, beta 9.40 — an Medical - Pharmaceuticals name. P/E, P/B, EV/EBITDA, margins, return on equity, current ratio and debt coverage, each shown against the company's own history.
Dividend Analysis
Yield, payout ratio, and dividend coverage metrics.
Dividend history, yield and payout sustainability for Canopus BioPharma Incorporated. Canopus BioPharma Incorporated does not currently pay a regular dividend, so this section tracks capacity rather than history. Per-share payments, yield over time, payout ratio and growth streak, with coverage measured against free cash flow.
Earnings Analysis
EPS history, beat rate, and upcoming earnings reports.
Reported vs. expected earnings history for Canopus BioPharma Incorporated. Trailing twelve-month EPS for Canopus BioPharma Incorporated stands at -$0.0070. EPS surprises by quarter, revenue against estimates, and the upcoming reporting date.
Financial Statements
Income statement, balance sheet, and cash flow statements.
Income statement, balance sheet and cash flow history for Canopus BioPharma Incorporated. Canopus BioPharma Incorporated has reported as a listed company since 1999. Annual and quarterly filings with period-over-period comparison, so you can trace how revenue, margins and cash generation have moved.
Comparables
List of peer companies in the same industry.
Canopus BioPharma Incorporated valued side by side against its closest peers. Canopus BioPharma Incorporated is measured against Medical - Pharmaceuticals peers within the Healthcare sector. Peer-relative multiples and operating metrics, so the valuation is read in the context of its own sector rather than in isolation.
Institutional Ownership
PremiumWhich funds and firms own the stock.
Which institutions hold Canopus BioPharma Incorporated, and how their positions are changing. At a $455,071 market value, institutional positions materially move Canopus BioPharma Incorporated's register. Top holders, position sizes, and quarter-over-quarter accumulation or distribution from regulatory filings. Included with FRC Premium.
Insider Trading
PremiumRecent buying and selling by company executives.
Buying and selling by Canopus BioPharma Incorporated executives and directors. Shares of Canopus BioPharma Incorporated have traded between $0.0000 and $0.0001 over the past 52 weeks — context for the timing of the transactions below. Insider transactions as disclosed to regulators, with role, size and date — the clearest read on how the people running the company are positioned. Included with FRC Premium.
Senate Trading
PremiumU.S. Senator disclosures filed under the STOCK Act.
U.S. Senate disclosures naming Canopus BioPharma Incorporated. Canopus BioPharma Incorporated is a $455,071 Healthcare company. Senators' reported transactions in this security, alongside the fundamentals — a signal most research platforms leave out entirely. Included with FRC Premium.
House Trading
PremiumU.S. Representative disclosures filed under the STOCK Act.
U.S. House of Representatives disclosures naming Canopus BioPharma Incorporated. Representatives' reported transactions in this security, shown next to the company's fundamentals. Included with FRC Premium.
News
Latest headlines and market coverage.
Latest headlines and company announcements for Canopus BioPharma Incorporated. Coverage tracks Canopus BioPharma Incorporated within Medical - Pharmaceuticals (Healthcare). Press releases and market coverage, newest first.